IL130324A0 - Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators - Google Patents

Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators

Info

Publication number
IL130324A0
IL130324A0 IL13032499A IL13032499A IL130324A0 IL 130324 A0 IL130324 A0 IL 130324A0 IL 13032499 A IL13032499 A IL 13032499A IL 13032499 A IL13032499 A IL 13032499A IL 130324 A0 IL130324 A0 IL 130324A0
Authority
IL
Israel
Prior art keywords
alkyl
iron chelators
treatment
pharmaceutical compositions
neurodegenerative disorders
Prior art date
Application number
IL13032499A
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Technion Res & Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Technion Res & Dev Foundation filed Critical Yeda Res & Dev
Priority to IL13032499A priority Critical patent/IL130324A0/xx
Publication of IL130324A0 publication Critical patent/IL130324A0/xx
Priority to DE60035988T priority patent/DE60035988T2/de
Priority to PCT/IL2000/000332 priority patent/WO2000074664A2/en
Priority to AT00935453T priority patent/ATE369858T1/de
Priority to US10/009,300 priority patent/US6855711B1/en
Priority to EP00935453A priority patent/EP1189606B1/de
Priority to IL14694400A priority patent/IL146944A0/xx
Priority to AU50992/00A priority patent/AU769582B2/en
Priority to CA002374317A priority patent/CA2374317C/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13032499A 1999-06-07 1999-06-07 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators IL130324A0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL13032499A IL130324A0 (en) 1999-06-07 1999-06-07 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
DE60035988T DE60035988T2 (de) 1999-06-07 2000-06-07 Eisenchelatoren und arzneimittel enthaltend eisenchelatoren zur behandlung von neurodegenerativen erkrankungen
PCT/IL2000/000332 WO2000074664A2 (en) 1999-06-07 2000-06-07 Novel iron chelators and pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders
AT00935453T ATE369858T1 (de) 1999-06-07 2000-06-07 Eisenchelatoren und arzneimittel enthaltend eisenchelatoren zur behandlung von neurodegenerativen erkrankungen
US10/009,300 US6855711B1 (en) 1999-06-07 2000-06-07 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
EP00935453A EP1189606B1 (de) 1999-06-07 2000-06-07 Eisenchelatoren und arzneimittel enthaltend eisenchelatoren zur behandlung von neurodegenerativen erkrankungen
IL14694400A IL146944A0 (en) 1999-06-07 2000-06-07 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
AU50992/00A AU769582B2 (en) 1999-06-07 2000-06-07 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
CA002374317A CA2374317C (en) 1999-06-07 2000-06-07 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13032499A IL130324A0 (en) 1999-06-07 1999-06-07 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators

Publications (1)

Publication Number Publication Date
IL130324A0 true IL130324A0 (en) 2000-06-01

Family

ID=11072888

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13032499A IL130324A0 (en) 1999-06-07 1999-06-07 Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators

Country Status (8)

Country Link
US (1) US6855711B1 (de)
EP (1) EP1189606B1 (de)
AT (1) ATE369858T1 (de)
AU (1) AU769582B2 (de)
CA (1) CA2374317C (de)
DE (1) DE60035988T2 (de)
IL (1) IL130324A0 (de)
WO (1) WO2000074664A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565185A4 (de) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation Neuroprotektive eisenchelatoren und pharmazeutische zusammensetzungen damit
CN101252913A (zh) * 2005-09-02 2008-08-27 纽洛桑生物医药有限公司 含有铁螯合剂的药物组合物
WO2007048846A1 (de) * 2005-10-27 2007-05-03 Neuraxo Biopharmaceuticals Gmbh Verwendung von eisen chelatisierenden verbindungen, zyklisches adenosinmonophosphat erhöhende verbindungen oder kombinationen davon zur behandlung von axonalen läsionen im zns
FR2913976B1 (fr) 2007-03-23 2013-04-26 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers.
CN101679263B (zh) 2007-03-28 2014-01-15 阿普泰克斯科技公司 去铁酮的氟化衍生物
EP2268282B1 (de) * 2008-04-25 2014-10-29 Apotex Technologies Inc. Flüssige formulierung von deferipron mit angenehmem geschmack
CA2751033A1 (en) 2009-01-29 2010-08-05 Yeda Research And Development Co. Ltd. Neuroprotective multifunctional compounds and pharmaceutical compositions comprising them
GEP20146008B (en) 2009-07-03 2014-01-10 Apotex Tech Inc Fluorinated derivatives of 3-hydroxypyridin-4-ones
CN103298790A (zh) 2010-08-13 2013-09-11 维里奈奥公司 神经保护作用和神经修复作用的铁螯合剂和单胺氧化酶抑制剂及其用途
CA2826192A1 (en) 2011-01-31 2012-08-09 The Government Of The United States, As Represented By The Secretary Of The Army Methods and compositions for treating bacterial infections with iron chelators
WO2013115793A1 (en) 2012-01-31 2013-08-08 Varinel, Inc. Iron chelators and uses thereof
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652519A (en) 1983-02-03 1987-03-24 Yeda Research And Development Company Limited Bifunctional chelating agents and process for their production
JPS63238060A (ja) 1987-03-26 1988-10-04 Maruho Kk キノリン誘導体
US5202451A (en) 1988-02-17 1993-04-13 Neorx Corporation Anchimeric radiometal chelating compounds

Also Published As

Publication number Publication date
WO2000074664A3 (en) 2001-09-27
DE60035988D1 (de) 2007-09-27
ATE369858T1 (de) 2007-09-15
CA2374317C (en) 2009-12-01
CA2374317A1 (en) 2000-12-14
AU769582B2 (en) 2004-01-29
US6855711B1 (en) 2005-02-15
WO2000074664A2 (en) 2000-12-14
DE60035988T2 (de) 2008-05-08
EP1189606A2 (de) 2002-03-27
EP1189606B1 (de) 2007-08-15
AU5099200A (en) 2000-12-28

Similar Documents

Publication Publication Date Title
MY153023A (en) Tropane derivatives useful in therapy
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
WO2001009103A3 (en) Imidazole antiproliferative agents
TW249234B (de)
MX9504349A (es) Derivados de aroilpiperidina.
IL130324A0 (en) Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators
NZ334954A (en) Substituted heterocycles as anti-tumor agents
AU2492500A (en) Aspartic protease inhibitors, compositions, and associated therapeutic methods
TW427990B (en) Process for preparing substituted oxazinoindole carboxamides and the intermediates therefor
DE69828197D1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
GB9929297D0 (en) Process
WO2000071538A3 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
ES8300095A1 (es) "un procedimiento para preparar derivados de halofenil-piridil-alilamina".
NO20033049D0 (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1
WO2002017954A1 (fr) Medicaments contre la maladie de parkinson
DE69001004D1 (de) Zusammensetzung gegen leberkrankheiten.
AU2406700A (en) 3,4-dihydro-2h-benzo(1,4)oxazinyl-methyl(3-(1h-indol-3-yl)-a kyl)-amines
EP0210815A3 (de) 6-Beta-(alpha-veräthertes oxyimino)-acylamino-Penicillansäure-Derivate, ihre Herstellung und Verwendung
PT82693B (en) Process for the preparation of benzaldoxime carbamate derivatives having a fungicidal effect
AU2178199A (en) Azetidinecarboxamide derivatives for the treatment of cns disorders
ES8405409A1 (es) Un procedimiento para la preparacion de derivados de b-lactama.
TW275629B (de)
PL364794A1 (en) 2-aminotetralin derivatives for the therapy of glaucoma
GB8907306D0 (en) New compositions of matter
ES8302719A1 (es) Un procedimiento para preparar compuestos de cefem